Antibody Responses to SARS-CoV-2 Following an Outbreak Among Marine Recruits With Asymptomatic or Mild Infection.
We investigated serological responses following a SARS-CoV-2 outbreak in spring 2020 on a US Marine recruit training base. 147 participants that were isolated during an outbreak of respiratory illness were enrolled in this study, with visits approximately 6 and 10 weeks post-outbreak (PO). This cohort is comprised of young healthy adults, ages 18-26, with a high rate of asymptomatic infection or mild symptoms, and therefore differs from previously reported longitudinal studies on humoral responses to SARS-CoV-2, which often focus on more diverse age populations and worse clinical presentation. 80.9% (119/147) of the participants presented with circulating IgG antibodies against SARS-CoV-2 spike (S) receptor-binding domain (RBD) at 6 weeks PO, of whom 97.3% (111/114) remained positive, with significantly decreased levels, at 10 weeks PO. Neutralizing activity was detected in all sera from SARS-CoV-2 IgG positive participants tested (n=38) at 6 and 10 weeks PO, without significant loss between time points. IgG and IgA antibodies against SARS-CoV-2 RBD, S1, S2, and the nucleocapsid (N) protein, as well neutralization activity, were generally comparable between those participants that had asymptomatic infection or mild disease. A multiplex assay including S proteins from SARS-CoV-2 and related zoonotic and human endemic betacoronaviruses revealed a positive correlation for polyclonal cross-reactivity to S after SARS-CoV-2 infection. Overall, young adults that experienced asymptomatic or mild SARS-CoV-2 infection developed comparable humoral responses, with no decrease in neutralizing activity at least up to 10 weeks after infection.
['Ramos|Irene|I|', 'Goforth|Carl|C|', 'Soares-Schanoski|Alessandra|A|', 'Weir|Dawn L|DL|', 'Samuels|Emily C|EC|', 'Phogat|Shreshta|S|', 'Meyer|Michelle|M|', 'Huang|Kai|K|', 'Pietzsch|Colette A|CA|', 'Ge|Yongchao|Y|', 'Pike|Brian L|BL|', 'Regeimbal|James|J|', 'Simons|Mark P|MP|', 'Termini|Michael S|MS|', 'Vangeti|Sindhu|S|', 'Marjanovic|Nada|N|', 'Lizewski|Stephen|S|', 'Lizewski|Rhonda|R|', 'George|Mary-Catherine|MC|', 'Nair|Venugopalan D|VD|', 'Smith|Gregory R|GR|', 'Mao|Weiguang|W|', 'Chikina|Maria|M|', 'Broder|Christopher C|CC|', 'Laing|Eric D|ED|', 'Bukreyev|Alexander|A|', 'Sealfon|Stuart C|SC|', 'Letizia|Andrew G|AG|']
D000293:Adolescent D000328:Adult D057134:Antibodies, Neutralizing D000914:Antibodies, Viral D000917:Antibody Formation D058070:Asymptomatic Diseases D000086382:COVID-19 D015331:Cohort Studies D004196:Disease Outbreaks D018450:Disease Progression D005260:Female D006801:Humans D008297:Male D008889:Military Personnel D000086402:SARS-CoV-2 D064370:Spike Glycoprotein, Coronavirus D014481:United States D055815:Young Adult
antibodies SARS-COV-2 outbreak young adults COVID-19